首页 > 最新文献

Ideggyogyaszati Szemle-Clinical Neuroscience最新文献

英文 中文
[Non-drug therapies in the treatment of migraine]. [治疗偏头痛的非药物疗法]。
IF 0.6 4区 医学 Q4 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.18071/isz.79.0007
Marianna Tóth

The treatment of migraine is complex, and non-pharmacological methods are useful and necessary complements or alternatives to pharmacotherapy. We reviewed techniques that can be recommended for the treatment of episodic and chronic migraine attacks and prevention, and described methods for which there is no evidence of effectiveness. The most important of the therapies that can be recommended for migraine prevention are the elimination of provoking factors, lifestyle modification and regular exercise, and some diets have also been suggested to be beneficial. Based on the available evidence, supplementing preventive treatment with acupuncture or psychological therapy reduces the frequency of headaches in episodic migraine, and some psychological techniques may also be recommended for chronic migraine or attack therapy. Among the nutritional supplements, the effectiveness of riboflavin, magnesium and Q10 have been clinically proven to be effective in the preventive treatment of migraine. Interventional and invasive neuromodulation techniques are not widespread due to specific equipment requirements and increased risk of complications, however, based on good tolerability, some non-invasive methods can be recommended in the treatment of chronic migraine attacks and prevention. A large proportion of patients try other complementary or alternative methods, the efficacy or ineffectiveness of which has not been clinically proven, and therefore cannot be recommended.

偏头痛的治疗是复杂的,非药物方法是药物治疗的有用和必要的补充或替代。我们回顾了可以推荐用于治疗和预防发作性和慢性偏头痛发作的技术,并描述了没有证据表明有效的方法。预防偏头痛最重要的治疗方法是消除诱发因素,改变生活方式和定期锻炼,一些饮食也被认为是有益的。根据现有的证据,用针灸或心理治疗补充预防治疗可以减少发作性偏头痛的头痛频率,一些心理技术也可以推荐用于慢性偏头痛或发作性偏头痛治疗。在营养补充剂中,核黄素、镁和辅酶Q10的有效性已被临床证明对偏头痛的预防治疗有效。由于特定的设备要求和并发症风险增加,介入和侵入性神经调节技术并不普遍,然而,基于良好的耐受性,一些非侵入性方法可以推荐用于慢性偏头痛发作的治疗和预防。很大比例的患者尝试其他补充或替代方法,其疗效或无效尚未得到临床证明,因此不能推荐。
{"title":"[Non-drug therapies in the treatment of migraine].","authors":"Marianna Tóth","doi":"10.18071/isz.79.0007","DOIUrl":"https://doi.org/10.18071/isz.79.0007","url":null,"abstract":"<p><p>The treatment of migraine is complex, and non-pharmacological methods are useful and necessary complements or alternatives to pharmacotherapy. We reviewed techniques that can be recommended for the treatment of episodic and chronic migraine attacks and prevention, and described methods for which there is no evidence of effectiveness. The most important of the therapies that can be recommended for migraine prevention are the elimination of provoking factors, lifestyle modification and regular exercise, and some diets have also been suggested to be beneficial. Based on the available evidence, supplementing preventive treatment with acupuncture or psychological therapy reduces the frequency of headaches in episodic migraine, and some psychological techniques may also be recommended for chronic migraine or attack therapy. Among the nutritional supplements, the effectiveness of riboflavin, magnesium and Q10 have been clinically proven to be effective in the preventive treatment of migraine. Interventional and invasive neuromodulation techniques are not widespread due to specific equipment requirements and increased risk of complications, however, based on good tolerability, some non-invasive methods can be recommended in the treatment of chronic migraine attacks and prevention. A large proportion of patients try other complementary or alternative methods, the efficacy or ineffectiveness of which has not been clinically proven, and therefore cannot be recommended.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"79 1-2","pages":"7-16"},"PeriodicalIF":0.6,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stroke management challenges and innovations in Hungary and China: A comparative study. 匈牙利和中国中风管理的挑战和创新:比较研究。
IF 0.6 4区 医学 Q4 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.18071/isz.79.0017
Anna Gaál, Yufei Wei, Reziya Abuduxukuer, Dániel Bereczki, László Csiba, László Oláh, Liping Liu

Background and purpose: Stroke is a leading cause of death globally, placing a particularly high burden on Hungary and China. Our study aimed to compare the epidemiology, acute management, and stroke prevention strategies based on Hungarian and Chinese data.

Methods: We conducted a comprehensive literature review using Hungarian and Chinese epidemiological data, national health reports and guidelines, local protocols for stroke management, and publications related to prevention strategies. Data collection involved PubMed and MEDLINE databases; we also included results from the Global Burden of Disease Study to compare stroke incidence and mortality data in the two populations. The analysis of data from the two countries allowed for the identification of key trends.

Results: Despite the global decline in stroke-related mortality, Hungary's age-standardized stroke mortality rate remains above the European average, while a 32% increase has been seen in stroke-related deaths since 1990 in China. Even with the implementation of national stroke prevention initiatives, an increasing trend is observed in the prevalence of cardiovascular risk factors in both countries. The stroke management protocols of both nations align with international guidelines, including recommendations for intravenous thrombolysis and mechanical thrombectomy, as well as efforts to establish stroke center networks and systems that enhance prehospital care efficiency.

Conclusion: While advancements in stroke management are evident in both Hungary and China, challenges persist in optimizing stroke prevention, reducing "stroke-to-needle time", and expanding rehabilitation services.

背景和目的:中风是全球死亡的主要原因,对匈牙利和中国造成了特别沉重的负担。我们的研究旨在比较匈牙利和中国数据的流行病学、急性管理和卒中预防策略。方法:我们对匈牙利和中国的流行病学数据、国家卫生报告和指南、地方脑卒中管理方案以及与预防策略相关的出版物进行了全面的文献综述。数据收集涉及PubMed和MEDLINE数据库;我们还纳入了全球疾病负担研究的结果,以比较两个人群的卒中发病率和死亡率数据。对这两个国家的数据进行了分析,从而确定了主要趋势。结果:尽管全球中风相关死亡率下降,但匈牙利的年龄标准化中风死亡率仍高于欧洲平均水平,而中国自1990年以来中风相关死亡率增加了32%。即使实施了国家脑卒中预防措施,心血管危险因素在这两个国家的患病率仍呈上升趋势。两国的卒中管理方案与国际指南保持一致,包括静脉溶栓和机械取栓的建议,以及努力建立卒中中心网络和系统,以提高院前护理效率。结论:尽管匈牙利和中国在脑卒中管理方面取得了明显进步,但在优化脑卒中预防、缩短“脑卒中到针头注射时间”和扩大康复服务方面仍然存在挑战。
{"title":"Stroke management challenges and innovations in Hungary and China: A comparative study.","authors":"Anna Gaál, Yufei Wei, Reziya Abuduxukuer, Dániel Bereczki, László Csiba, László Oláh, Liping Liu","doi":"10.18071/isz.79.0017","DOIUrl":"https://doi.org/10.18071/isz.79.0017","url":null,"abstract":"<p><strong>Background and purpose: </strong>Stroke is a leading cause of death globally, placing a particularly high burden on Hungary and China. Our study aimed to compare the epidemiology, acute management, and stroke prevention strategies based on Hungarian and Chinese data.</p><p><strong>Methods: </strong>We conducted a comprehensive literature review using Hungarian and Chinese epidemiological data, national health reports and guidelines, local protocols for stroke management, and publications related to prevention strategies. Data collection involved PubMed and MEDLINE databases; we also included results from the Global Burden of Disease Study to compare stroke incidence and mortality data in the two populations. The analysis of data from the two countries allowed for the identification of key trends.</p><p><strong>Results: </strong>Despite the global decline in stroke-related mortality, Hungary's age-standardized stroke mortality rate remains above the European average, while a 32% increase has been seen in stroke-related deaths since 1990 in China. Even with the implementation of national stroke prevention initiatives, an increasing trend is observed in the prevalence of cardiovascular risk factors in both countries. The stroke management protocols of both nations align with international guidelines, including recommendations for intravenous thrombolysis and mechanical thrombectomy, as well as efforts to establish stroke center networks and systems that enhance prehospital care efficiency.</p><p><strong>Conclusion: </strong>While advancements in stroke management are evident in both Hungary and China, challenges persist in optimizing stroke prevention, reducing \"stroke-to-needle time\", and expanding rehabilitation services.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"79 1-2","pages":"17-24"},"PeriodicalIF":0.6,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy of Gasserian ganglion block and pulsed radiofrequency in the treatment of chronic cluster headache: A retrospective cohort study. Gasserian神经节阻滞和脉冲射频治疗慢性丛集性头痛的疗效:一项回顾性队列研究。
IF 0.6 4区 医学 Q4 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.18071/isz.79.0045
Mustafa Kemal İlik, Faik İlik, Devrimsel Harika Ertem

Background and purpose: To assess the effectiveness of Gasserian ganglion block and pulsed radiofrequency in managing chronic cluster headache (CCH).

Methods: We enrolled 38 patients with treatment-resistant CCH who were admitted between March 2020 and January 2024 and underwent Gasserian ganglion pulsed radiofrequency (PRF) combined with a ganglion block. Patients were followed up for six months, with pain severity assessed using the 0-10 Numerical Pain Rating Scale (NPRS).

Results: Among 38 patients (mean age 30.8 ± 8.6 years), the mean headache duration before treatment was 29.72 ± 17.65 months, and patients reported an average of 19.11 ± 2.01 headache days per month. Before the procedure, the mean NPRS score was 8.81 ± 0.80, which significantly decreased to 4.13 ± 3.74 post-treatment (p=0.001) and further declined to 3.38 ± 1.59 at the six-month follow-up (p=0.002). Four patients became pain-free, while 13 did not benefit from the procedure. The mean number of headache days dropped to 6.40 ± 4.22 per month (p.

Conclusion: Our results showed a significant reduction in pain and attack frequency with Gasserian ganglion block and PRF for treating CCH resistant to standard therapies, with many patients requiring less medication. The procedure was well-tolerated, with mild and temporary side effects; these findings suggest it may be a promising option for drug-resistant CCH. Future studies should include controlled trials for further evaluation.

背景与目的:评价Gasserian神经节阻滞和脉冲射频治疗慢性丛集性头痛(CCH)的有效性。方法:我们招募了38名在2020年3月至2024年1月期间入院的难治性CCH患者,并接受了Gasserian神经节脉冲射频(PRF)联合神经节阻滞治疗。患者随访6个月,使用0-10数值疼痛评定量表(NPRS)评估疼痛严重程度。结果:38例患者(平均年龄30.8±8.6岁),治疗前平均头痛持续时间为29.72±17.65个月,每月平均头痛天数为19.11±2.01天。术前平均NPRS评分为8.81±0.80分,治疗后为4.13±3.74分(p=0.001), 6个月随访时为3.38±1.59分(p=0.002)。4名患者无疼痛,而13名患者没有从手术中受益。结论:我们的研究结果显示,使用Gasserian神经节阻滞和PRF治疗对标准疗法有耐药性的CCH,疼痛和发作频率显著降低,许多患者需要更少的药物。该手术耐受性良好,副作用轻微且短暂;这些发现表明,它可能是耐药CCH的一个有希望的选择。未来的研究应包括进一步评价的对照试验。
{"title":"The efficacy of Gasserian ganglion block and pulsed radiofrequency in the treatment of chronic cluster headache: A retrospective cohort study.","authors":"Mustafa Kemal İlik, Faik İlik, Devrimsel Harika Ertem","doi":"10.18071/isz.79.0045","DOIUrl":"https://doi.org/10.18071/isz.79.0045","url":null,"abstract":"<p><strong>Background and purpose: </strong>To assess the effectiveness of Gasserian ganglion block and pulsed radiofrequency in managing chronic cluster headache (CCH).</p><p><strong>Methods: </strong>We enrolled 38 patients with treatment-resistant CCH who were admitted between March 2020 and January 2024 and underwent Gasserian ganglion pulsed radiofrequency (PRF) combined with a ganglion block. Patients were followed up for six months, with pain severity assessed using the 0-10 Numerical Pain Rating Scale (NPRS).</p><p><strong>Results: </strong>Among 38 patients (mean age 30.8 ± 8.6 years), the mean headache duration before treatment was 29.72 ± 17.65 months, and patients reported an average of 19.11 ± 2.01 headache days per month. Before the procedure, the mean NPRS score was 8.81 ± 0.80, which significantly decreased to 4.13 ± 3.74 post-treatment (p=0.001) and further declined to 3.38 ± 1.59 at the six-month follow-up (p=0.002). Four patients became pain-free, while 13 did not benefit from the procedure. The mean number of headache days dropped to 6.40 ± 4.22 per month (p.</p><p><strong>Conclusion: </strong>Our results showed a significant reduction in pain and attack frequency with Gasserian ganglion block and PRF for treating CCH resistant to standard therapies, with many patients requiring less medication. The procedure was well-tolerated, with mild and temporary side effects; these findings suggest it may be a promising option for drug-resistant CCH. Future studies should include controlled trials for further evaluation.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"79 1-2","pages":"45-52"},"PeriodicalIF":0.6,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epilepsy during pregnancy in emergency department setting. 妊娠期间癫痫在急诊科设置。
IF 0.6 4区 医学 Q4 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.18071/isz.79.0027
Sarper Sevdimbas, Selen Acehan, Salim Satar, Muge Gulen, İhsan Dengiz, Figen Topalak

Background and purpose: Pregnant women diagnosed with epilepsy are in the high-risk group for maternal and neonatal complications. We aimed to analyze pregnant patients admitting to the emergency department (ED) with epileptic seizures, to investigate the treatment regimens applied during pregnancy, and to examine the effects of seizure frequency during pregnancy on neonatal outcomes.

Methods: This retrospective study included 53 pregnant epilepsy patients presenting to the ED with seizures. Demographic and clinical data, medication use, outcomes, along with neonatal APGAR scores, were recorded using a standard form.

Results: In the study, 32.1% of patients were hospitalized, and 41.5% discontinued their medication, with 47% of this subgroup experiencing hospitalization (p.

Conclusion: This study reveals that the hospitalization rates of pregnant patients presenting to the ED with epileptic seizures are significantly affected by factors such as the type of antiepileptic drug used, medication compliance, and admission lactate levels. Additionally, irregular use of medications is associated with higher incidences of seizures during pregnancy and adverse neonatal outcomes.

背景和目的:被诊断为癫痫的孕妇属于孕产妇和新生儿并发症的高危人群。我们的目的是分析急诊科(ED)癫痫发作的孕妇,探讨妊娠期间应用的治疗方案,并检查妊娠期间癫痫发作频率对新生儿结局的影响。方法:回顾性研究了53例以癫痫发作为主要表现的妊娠癫痫患者。使用标准表格记录人口统计学和临床数据、药物使用、结果以及新生儿APGAR评分。结果:本研究中32.1%的患者住院,41.5%的患者停药,其中47%的患者住院(p.结论:本研究显示,抗癫痫药物类型、用药依从性、入院乳酸水平等因素显著影响孕妇癫痫发作至ED的住院率。此外,不规律使用药物与妊娠期间癫痫发作的高发生率和不良新生儿结局有关。
{"title":"Epilepsy during pregnancy in emergency department setting.","authors":"Sarper Sevdimbas, Selen Acehan, Salim Satar, Muge Gulen, İhsan Dengiz, Figen Topalak","doi":"10.18071/isz.79.0027","DOIUrl":"https://doi.org/10.18071/isz.79.0027","url":null,"abstract":"<p><strong>Background and purpose: </strong>Pregnant women diagnosed with epilepsy are in the high-risk group for maternal and neonatal complications. We aimed to analyze pregnant patients admitting to the emergency department (ED) with epileptic seizures, to investigate the treatment regimens applied during pregnancy, and to examine the effects of seizure frequency during pregnancy on neonatal outcomes.</p><p><strong>Methods: </strong>This retrospective study included 53 pregnant epilepsy patients presenting to the ED with seizures. Demographic and clinical data, medication use, outcomes, along with neonatal APGAR scores, were recorded using a standard form.</p><p><strong>Results: </strong>In the study, 32.1% of patients were hospitalized, and 41.5% discontinued their medication, with 47% of this subgroup experiencing hospitalization (p.</p><p><strong>Conclusion: </strong>This study reveals that the hospitalization rates of pregnant patients presenting to the ED with epileptic seizures are significantly affected by factors such as the type of antiepileptic drug used, medication compliance, and admission lactate levels. Additionally, irregular use of medications is associated with higher incidences of seizures during pregnancy and adverse neonatal outcomes.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"79 1-2","pages":"27-34"},"PeriodicalIF":0.6,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Temporal muscle thickness: A new tool to assess sarcopenia in Parkinson's disease. 颞肌厚度:评估帕金森病肌肉减少症的新工具。
IF 0.6 4区 医学 Q4 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.18071/isz.79.0053
Nedim Ongun

Background and purpose: Parkinson's disease is a neurodegenerative disorder cha- racterized by motor symptoms such as tremor, rigidity and bradykinesia. However, it can also lead to non-motor symptoms such as cognitive impairments and sarcopenia. The aim of this study is to evaluate the relationship between screening and diagnostic methods for sarcopenia and temporal muscle thickness in Parkinson's disease patients, and to assess the utility of temporal muscle thickness measurement as an indicator of sarcopenia.

Methods: An observational study was conducted with Parkinson's disease patients in a single neurology clinic. A total of 38 patients were included. Temporal muscle thickness was measured manually using brain computed tomography and muscle strength was assessed with handheld dynamometer. Malnutrition risk, sarcopenia risk and functional disease stage (Movement Disorders Society-Unified Parkinson's Disease Rating Scale, Hoehn and Yahr stage) were also evaluated in entire group.

Results: The mean temporal muscle thickness and handgrip strength were 6.12±1.05 mm and 18.30±5.55 kg respectively. Mean disease duration was 8.13±3.11 years and the median H&Y stage was 2.21. There was a significant correlation between temporal muscle thickness and age (r=-0.326, p=0.046), SARC-F score (r=-0.738, p.

Conclusion: Measurement of temporal muscle thickness using brain computed tomography in Parkinson' s disease patients may be a useful method for muscle mass determination and treatment of sarcopenia.

背景与目的:帕金森病是一种神经退行性疾病,以震颤、强直和运动迟缓等运动症状为特征。然而,它也会导致非运动症状,如认知障碍和肌肉减少症。本研究的目的是评估帕金森病患者肌减少症的筛查和诊断方法与颞肌厚度之间的关系,并评估颞肌厚度测量作为肌减少症指标的效用。方法:在一个神经病学诊所对帕金森病患者进行观察性研究。共纳入38例患者。人工脑计算机断层扫描测量颞肌厚度,手持式测功机评估肌肉力量。同时对全组的营养不良风险、肌肉减少风险和功能疾病分期(运动障碍学会-统一帕金森病评定量表、Hoehn和Yahr分期)进行评估。结果:平均颞肌厚度为6.12±1.05 mm,握力为18.30±5.55 kg。平均病程为8.13±3.11年,中位H&Y分期为2.21年。颞肌厚度与年龄(r=-0.326, p=0.046)、SARC-F评分(r=-0.738, p)有显著相关性。结论:脑ct测量帕金森病患者颞肌厚度可能是测定肌肉质量和治疗肌少症的有效方法。
{"title":"Temporal muscle thickness: A new tool to assess sarcopenia in Parkinson's disease.","authors":"Nedim Ongun","doi":"10.18071/isz.79.0053","DOIUrl":"https://doi.org/10.18071/isz.79.0053","url":null,"abstract":"<p><strong>Background and purpose: </strong>Parkinson's disease is a neurodegenerative disorder cha- racterized by motor symptoms such as tremor, rigidity and bradykinesia. However, it can also lead to non-motor symptoms such as cognitive impairments and sarcopenia. The aim of this study is to evaluate the relationship between screening and diagnostic methods for sarcopenia and temporal muscle thickness in Parkinson's disease patients, and to assess the utility of temporal muscle thickness measurement as an indicator of sarcopenia.</p><p><strong>Methods: </strong>An observational study was conducted with Parkinson's disease patients in a single neurology clinic. A total of 38 patients were included. Temporal muscle thickness was measured manually using brain computed tomography and muscle strength was assessed with handheld dynamometer. Malnutrition risk, sarcopenia risk and functional disease stage (Movement Disorders Society-Unified Parkinson's Disease Rating Scale, Hoehn and Yahr stage) were also evaluated in entire group.</p><p><strong>Results: </strong>The mean temporal muscle thickness and handgrip strength were 6.12±1.05 mm and 18.30±5.55 kg respectively. Mean disease duration was 8.13±3.11 years and the median H&Y stage was 2.21. There was a significant correlation between temporal muscle thickness and age (r=-0.326, p=0.046), SARC-F score (r=-0.738, p.</p><p><strong>Conclusion: </strong>Measurement of temporal muscle thickness using brain computed tomography in Parkinson' s disease patients may be a useful method for muscle mass determination and treatment of sarcopenia.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"79 1-2","pages":"53-57"},"PeriodicalIF":0.6,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between headache types and severity with psychiatric comorbidity in adolescents. 青少年头痛类型和严重程度与精神共病的关系。
IF 0.6 4区 医学 Q4 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.18071/isz.79.0059
İbrahim Adak, Zeynep Ece Toksoy, Oğuz Bilal Karakus, Büşranur Oğuz Selçu, İpek Süzer Gamli, Özalp Ekinci, Füsun Mayda Domaç

Background and purpose: Headache is a prevalent health concern among children and adolescents, affecting approximately 54.4% of this population. It has a negative impact on functionality and is associated with psychiatric conditions. The aim of this study is to examine the prevalence and comorbidity of headache among adolescents seeking care at a child psychiatry outpatient clinic and to compare the psychiatric conditions of adolescents with and without headache by using specific assessment scales.

Methods: The study included a total of 306 patients (201 females, 105 males), comprising 108 adolescents with headache and 198 without headache, who were admitted to the Child&Adolescent Psychiatry Outpatient Clinic of a Mental and Nervous Diseas- es Training and Research Hospital. Patients presenting with complaints of headache were referred to the neurology department of the hospital for diagnosis and classification. The Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime Version-Turkish Adaptation was administered to all participants. Additional self-report scales including the State-Trait Anxiety Inventory (STAI) Forms 1 and 2, the Children's Depression Inventory (CDI), and the Young Internet Addiction Test - Short Form were given. Parents filled out the Conners' Parent Rating Scale and the Turgay DSM-IV-Based Child and Adolescent Disruptive Behavior Disorders Screening and Rating Scale.

Results: Among participants, 35.3% (n=108) have reported headache, divided into two subgroups; 58 had migraine and 50 had tension-type headache. The prevalence of Generalized Anxiety Disorder as a comorbid diagnosis was found to be significantly higher in the migraine group compared to those without headache (p=0.009). Nevertheless, there was no difference between migraine and tension type headache groups in terms of comorbid psychiatric diagnoses (p>0,05). The participants in both headache groups exhibited significantly elevated scores on the CDI, STAI-1 and STAI-2 in comparison to those without headache (p < 0.001). A positive correlation was identified between headache severity and both depression and trait anxiety severity among participants with headache. When classified according to the course of headache, chronic migraine was associated with higher Turgay and Conners scores, while chronic tension-type headache showed significantly higher CDI, STAI-1, and STAI-2 scores compared to episodic forms (p = .003-.038).

Conclusion: Psychiatric comorbidities are common in adolescents with headache, necessitating a comprehensive assessment that considers both conditions. This approach is crucial, as it has the potential to significantly influence the diagnosis, severity, progression, and treatment of these comorbidities, thereby ensuring comprehensive care and superior outcomes for affected individuals.

背景和目的:头痛是儿童和青少年中普遍存在的健康问题,约占该人群的54.4%。它对功能有负面影响,并与精神疾病有关。本研究的目的是检查在儿童精神病学门诊就诊的青少年中头痛的患病率和合并症,并通过使用特定的评估量表来比较有和没有头痛的青少年的精神状况。方法:本研究共纳入某精神神经疾病培训研究医院儿童与青少年精神病学门诊收治的306例患者(女201例,男105例),其中有头痛的青少年患者108例,无头痛的青少年患者198例。以头痛为主诉的患者被转介到医院神经内科进行诊断和分类。学龄儿童情感障碍和精神分裂症时间表-现在和终身版本-土耳其改编对所有参与者进行管理。附加的自我报告量表包括状态-特质焦虑量表(STAI)表格1和表格2、儿童抑郁量表(CDI)和青少年网络成瘾测试-简短表格。家长填写了Conners父母评定量表和Turgay基于dsm - iv的儿童和青少年破坏性行为障碍筛查评定量表。结果:在参与者中,35.3% (n=108)报告头痛,分为两个亚组;58人患有偏头痛,50人患有紧张性头痛。作为合并症诊断的广泛性焦虑障碍的患病率在偏头痛组中明显高于无头痛组(p=0.009)。然而,偏头痛组和紧张性头痛组在共病精神诊断方面没有差异(p < 0.05)。与无头痛组相比,两组患者的CDI、sti -1和sti -2得分均显著升高(p < 0.001)。在头痛患者中,头痛严重程度与抑郁和特质焦虑严重程度呈正相关。当根据头痛的病程分类时,慢性偏头痛与较高的Turgay和Conners评分相关,而慢性紧张性头痛与发作性头痛相比,CDI、sti -1和sti -2评分显著较高(p = 0.003 - 0.038)。结论:精神合并症在青少年头痛患者中很常见,有必要对这两种情况进行综合评估。这种方法至关重要,因为它有可能显著影响这些合并症的诊断、严重程度、进展和治疗,从而确保对受影响个体的全面护理和更好的结果。
{"title":"Relationship between headache types and severity with psychiatric comorbidity in adolescents.","authors":"İbrahim Adak, Zeynep Ece Toksoy, Oğuz Bilal Karakus, Büşranur Oğuz Selçu, İpek Süzer Gamli, Özalp Ekinci, Füsun Mayda Domaç","doi":"10.18071/isz.79.0059","DOIUrl":"https://doi.org/10.18071/isz.79.0059","url":null,"abstract":"<p><strong>Background and purpose: </strong>Headache is a prevalent health concern among children and adolescents, affecting approximately 54.4% of this population. It has a negative impact on functionality and is associated with psychiatric conditions. The aim of this study is to examine the prevalence and comorbidity of headache among adolescents seeking care at a child psychiatry outpatient clinic and to compare the psychiatric conditions of adolescents with and without headache by using specific assessment scales.</p><p><strong>Methods: </strong>The study included a total of 306 patients (201 females, 105 males), comprising 108 adolescents with headache and 198 without headache, who were admitted to the Child&Adolescent Psychiatry Outpatient Clinic of a Mental and Nervous Diseas- es Training and Research Hospital. Patients presenting with complaints of headache were referred to the neurology department of the hospital for diagnosis and classification. The Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime Version-Turkish Adaptation was administered to all participants. Additional self-report scales including the State-Trait Anxiety Inventory (STAI) Forms 1 and 2, the Children's Depression Inventory (CDI), and the Young Internet Addiction Test - Short Form were given. Parents filled out the Conners' Parent Rating Scale and the Turgay DSM-IV-Based Child and Adolescent Disruptive Behavior Disorders Screening and Rating Scale.</p><p><strong>Results: </strong>Among participants, 35.3% (n=108) have reported headache, divided into two subgroups; 58 had migraine and 50 had tension-type headache. The prevalence of Generalized Anxiety Disorder as a comorbid diagnosis was found to be significantly higher in the migraine group compared to those without headache (p=0.009). Nevertheless, there was no difference between migraine and tension type headache groups in terms of comorbid psychiatric diagnoses (p>0,05). The participants in both headache groups exhibited significantly elevated scores on the CDI, STAI-1 and STAI-2 in comparison to those without headache (p < 0.001). A positive correlation was identified between headache severity and both depression and trait anxiety severity among participants with headache. When classified according to the course of headache, chronic migraine was associated with higher Turgay and Conners scores, while chronic tension-type headache showed significantly higher CDI, STAI-1, and STAI-2 scores compared to episodic forms (p = .003-.038).</p><p><strong>Conclusion: </strong>Psychiatric comorbidities are common in adolescents with headache, necessitating a comprehensive assessment that considers both conditions. This approach is crucial, as it has the potential to significantly influence the diagnosis, severity, progression, and treatment of these comorbidities, thereby ensuring comprehensive care and superior outcomes for affected individuals.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"79 1-2","pages":"59-68"},"PeriodicalIF":0.6,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anterior and posterior parts of diaphragm: A search for the best recording sites and the relevant normative data with surface electrodes. 横膈膜前后部分:寻找最佳记录位置和表面电极的相关规范数据。
IF 0.6 4区 医学 Q4 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.18071/isz.79.0035
Volkan Tasdemir, Nermin Gorkem Sirin, Ali Emre Oge, Elif Kocasoy Orhan

Background and purpose: Phrenic nerve conduction studies, including comprehensive recording of compound muscle action potentials (CMAP) from all regions of the dia- phragm, can be useful in both neurolo-gical conditions affecting the phrenic nerve or diaphragm and non-neurological conditions such as COPD and GERD, and may have potential diagnostic value. It was aimed (a) to determine the most convenient stimulation and recording sites for phrenic nerve conduction studies (NCS), (b) to record CMAPs reflecting the activity of the posterior part of the diaphragm with surface recording electrodes, (c) to define normative values for these studies.

Methods: Sixty-three healthy subjects were included in the study and CMAPs were recorded simultaneously with two anterior and two posterior electrode derivations while stimulating the phrenic nerve behind the sternocleidomastoid muscle.

Results: Among the four different electrode placements, the recording electrode pairs providing the highest amplitude CMAPs were those placed 5 cm above the xiphoid process (active) and 16 cm laterally on the costal margin (reference). With this placement method, the upper limit of CMAP latency was 7.70 ms, the lower limit of base-topeak amplitude was 0.30 mV and the lower limit of peak-to-peak amplitude was 0.45 mV. Diaphragmatic CMAPs have been obtained from the majority of volunteers with surface electrodes placed in the posterior regions of the diaphragm, albeit with lower amplitude. Age is the only independent factor affecting the CMAP latency in this study.

Conclusion: Normative values with the best recording sites for phrenic NCSs were determined. The posterior aspect of the diaphragm could be recorded with surface electrodes despite the lower amplitude and reliability compared to the anterior part.

背景和目的:膈神经传导研究,包括膈神经所有区域的复合肌动作电位(CMAP)的全面记录,对影响膈神经或膈神经的神经系统疾病和非神经系统疾病(如COPD和GERD)都有帮助,并可能具有潜在的诊断价值。目的是(a)确定膈神经传导研究(NCS)最方便的刺激和记录部位,(b)用表面记录电极记录反映膈后部活动的cmap, (c)为这些研究定义规范值。方法:选取63名健康受试者,在刺激胸锁乳突肌后膈神经的同时,采用前后两个电极同时记录cmap。结果:在四种不同的电极放置位置中,记录电极对在剑突上方5cm处(活动)和肋缘外侧16cm处(参考)提供最高振幅的cmap。采用该放置方法,CMAP潜伏期上限为7.70 ms,基峰幅值下限为0.30 mV,峰间幅值下限为0.45 mV。通过将表面电极置于横膈膜后区,大多数志愿者获得了横膈膜cmap,尽管振幅较低。在本研究中,年龄是影响CMAP潜伏期的唯一独立因素。结论:确定了膈肌ncs的规范值和最佳记录部位。膜片的后侧面可以用表面电极记录,尽管与前部分相比,其振幅和可靠性较低。
{"title":"Anterior and posterior parts of diaphragm: A search for the best recording sites and the relevant normative data with surface electrodes.","authors":"Volkan Tasdemir, Nermin Gorkem Sirin, Ali Emre Oge, Elif Kocasoy Orhan","doi":"10.18071/isz.79.0035","DOIUrl":"https://doi.org/10.18071/isz.79.0035","url":null,"abstract":"<p><strong>Background and purpose: </strong>Phrenic nerve conduction studies, including comprehensive recording of compound muscle action potentials (CMAP) from all regions of the dia- phragm, can be useful in both neurolo-gical conditions affecting the phrenic nerve or diaphragm and non-neurological conditions such as COPD and GERD, and may have potential diagnostic value. It was aimed (a) to determine the most convenient stimulation and recording sites for phrenic nerve conduction studies (NCS), (b) to record CMAPs reflecting the activity of the posterior part of the diaphragm with surface recording electrodes, (c) to define normative values for these studies.</p><p><strong>Methods: </strong>Sixty-three healthy subjects were included in the study and CMAPs were recorded simultaneously with two anterior and two posterior electrode derivations while stimulating the phrenic nerve behind the sternocleidomastoid muscle.</p><p><strong>Results: </strong>Among the four different electrode placements, the recording electrode pairs providing the highest amplitude CMAPs were those placed 5 cm above the xiphoid process (active) and 16 cm laterally on the costal margin (reference). With this placement method, the upper limit of CMAP latency was 7.70 ms, the lower limit of base-topeak amplitude was 0.30 mV and the lower limit of peak-to-peak amplitude was 0.45 mV. Diaphragmatic CMAPs have been obtained from the majority of volunteers with surface electrodes placed in the posterior regions of the diaphragm, albeit with lower amplitude. Age is the only independent factor affecting the CMAP latency in this study.</p><p><strong>Conclusion: </strong>Normative values with the best recording sites for phrenic NCSs were determined. The posterior aspect of the diaphragm could be recorded with surface electrodes despite the lower amplitude and reliability compared to the anterior part.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"79 1-2","pages":"35-44"},"PeriodicalIF":0.6,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytotoxic lesion of corpus callosum associated with cerebral venous sinus thrombosis. 胼胝体细胞毒性病变伴脑静脉窦血栓形成。
IF 0.6 4区 医学 Q4 CLINICAL NEUROLOGY Pub Date : 2026-01-30 DOI: 10.18071/isz.79.0069
Inci Emekli, Ahmed Serkan Emekli

Introduction - Cytotoxic lesion of corpus callosum (CLOCC) is a rare but increasingly recognized entity. It is associated with various etiologies including drug-related toxicity, epilepsy, infections, metabolic disturbances, and many other conditions. Here we present a rare case of CLOCC due to cerebral venous sinus thrombosis (CVST) in the postpartum period.Case report - A 25-year-old female was admitted due to persistent headaches on the third day of her postpartum period. The neurological examination did not reveal any focal neurological signs. She was diagnosed with CVST and splenium of corpus callosum (SCC) lesion with imaging features of FLAIR/ T2/DWI hyperintensity, ADC hypointensity, and lack of contrast enhancement. Extensive work-up did not unveil any other etiology. She was treated with low-molecular-weight heparin, warfarin, and acetazolamide. Six weeks later, brain imaging showed recanalization of the cerebral sinuses without any signs of permanent lesion in SCC. She was symptom-free at the two-year follow-up.Conclusion - It is crucial to recognize CLOCC and thus to unveil and treat its potential etiology. CVST should be considered in CLOCC cases, particularly in patients with prothrombotic states such as the postpartum period.

胼胝体细胞毒性病变(CLOCC)是一种罕见但越来越被认识的疾病。它与多种病因有关,包括药物相关毒性、癫痫、感染、代谢紊乱和许多其他疾病。我们在此报告一例罕见的产后脑静脉窦血栓形成所致的CLOCC。病例报告-一名25岁女性因产后第三天持续头痛入院。神经学检查未发现任何局灶性神经征象。诊断为CVST及胼胝体脾(SCC)病变,影像学表现为FLAIR/ T2/DWI高信号,ADC低信号,缺乏增强。广泛的检查没有揭示任何其他病因。给予低分子肝素、华法林和乙酰唑胺治疗。6周后,脑成像显示脑窦再通,SCC无任何永久性病变迹象。在两年的随访中,她没有任何症状。结论-认识CLOCC,从而揭示和治疗其潜在病因是至关重要的。在CLOCC病例中应考虑CVST,特别是在有血栓前期状态的患者,如产后。
{"title":"Cytotoxic lesion of corpus callosum associated with cerebral venous sinus thrombosis.","authors":"Inci Emekli, Ahmed Serkan Emekli","doi":"10.18071/isz.79.0069","DOIUrl":"https://doi.org/10.18071/isz.79.0069","url":null,"abstract":"<p><p>Introduction - Cytotoxic lesion of corpus callosum (CLOCC) is a rare but increasingly recognized entity. It is associated with various etiologies including drug-related toxicity, epilepsy, infections, metabolic disturbances, and many other conditions. Here we present a rare case of CLOCC due to cerebral venous sinus thrombosis (CVST) in the postpartum period.Case report - A 25-year-old female was admitted due to persistent headaches on the third day of her postpartum period. The neurological examination did not reveal any focal neurological signs. She was diagnosed with CVST and splenium of corpus callosum (SCC) lesion with imaging features of FLAIR/ T2/DWI hyperintensity, ADC hypointensity, and lack of contrast enhancement. Extensive work-up did not unveil any other etiology. She was treated with low-molecular-weight heparin, warfarin, and acetazolamide. Six weeks later, brain imaging showed recanalization of the cerebral sinuses without any signs of permanent lesion in SCC. She was symptom-free at the two-year follow-up.Conclusion - It is crucial to recognize CLOCC and thus to unveil and treat its potential etiology. CVST should be considered in CLOCC cases, particularly in patients with prothrombotic states such as the postpartum period.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"79 1-2","pages":"69-72"},"PeriodicalIF":0.6,"publicationDate":"2026-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of propranolol with treatment-emergent akathisia during aripiprazole treatment. 心得安与阿立哌唑治疗期间出现的静坐症的关系。
IF 0.6 4区 医学 Q4 CLINICAL NEUROLOGY Pub Date : 2025-11-30 DOI: 10.18071/isz.78.0395
Ádám Menus, Ádám Kiss, Gábor Csukly, István Bitter, Katalin Monostory, János M Réthely
<p><strong>Background and purpose: </strong>Akathisia is a common side effect of aripiprazole treatment, which is associated with subjective distress for patients, and represents a frequent cause of treatment discontinuation. Propranolol and other beta-receptor blockers are commonly used for treatment of akathisia. Cytochrome P450 2D6 (CYP2D6) enzyme plays a major role in the metabolism of aripiprazole. Our previous study has shown that CYP2D6 inhibitory activity of beta-blockers (metoprolol and propranolol) may result in elevated aripiprazole plasma concentrations. The objective of the present retrospective study was to assess the prevalence of akathisia in patients receiving propranolol or metoprolol comedication, as well as in those not receiving any CYP2D6 inhibitors such as propranolol, metoprolol, risperidone.</p><p><strong>Methods: </strong>Using the data of our previous pharmacogenetic study involving 67 patients diagnosed with schizophrenia or schizoaffective disorder and receiving aripiprazole treat- ment, we retrospectively investigated the emergence of akathisia within 6 months following aripiprazole initiation. Information on the onset of akathisia was obtained from patients' medical records. The effects of CYP2D6 genotype, aripiprazole plasma concentration, propranolol and metoprolol comedication on the development of akathisia were analysed. The included patients had already been taking propranolol and metoprolol comedication prior to the initiation of aripiprazole and not for the treatment of akathisia.</p><p><strong>Results: </strong>Schizophrenia and schizoaffective disorder patients treated with propranolol had a significantly higher incidence of documented akathisia (38,5%) compared to the group not receiving CYP2D6 inhibitors (5.9%), and the group treated with metoprolol comedication (7.1%). Among the CYP2D6 inhibitors, only the administration of propranolol increased the risk of akathisia (Wald Chi2=5.5, p=0.02, OR=7.6 [95% CI=1.4-41.4]). The polymorphic CYP2D6 alleles resulting in low CYP2D6 function showed a statistical trend-level association with the occurrence of akathisia (Wald Chi2=2.6, p=0.11, OR=4.7 [95% CI=0.7-30.8]). In a subsequent analysis, we investigated the possible interaction of propranolol and CYP2D6 genotypes on the development of akathisia. The interaction model showed that the effect of propranolol was not dependent on CYP2D6 genotype (Wald Chi2=0.1, p=0.92), however, its independent effect remained significant (Wald Chi2=4.4, p=0.04).</p><p><strong>Conclusion: </strong>Our findings suggest that propranolol comedication increases the risk of the development of akathisia during aripiprazole treatment. It is of paramount importance to avoid propranolol comedication during aripiprazole treatment. However, two major limitations should be considered: akathisia was not assessed using a standardized clinical rating scale, and the majority of patients (80.6%) received antipsychotic combination therapy, which ma
背景和目的:静坐症是阿立哌唑治疗的常见副作用,与患者的主观痛苦有关,是中断治疗的常见原因。心得安和其他受体阻滞剂通常用于治疗静坐症。细胞色素P450 2D6 (CYP2D6)酶在阿立哌唑代谢中起重要作用。我们之前的研究表明-受体阻滞剂(美托洛尔和心得安)的CYP2D6抑制活性可能导致阿立哌唑血药浓度升高。本回顾性研究的目的是评估接受心得安或美托洛尔治疗的患者以及未接受任何CYP2D6抑制剂(如心得安、美托洛尔、利培酮)治疗的患者的静坐症患病率。方法:利用我们之前的药物遗传学研究数据,包括67例被诊断为精神分裂症或分裂情感性障碍并接受阿立哌唑治疗的患者,我们回顾性调查了阿立哌唑开始治疗后6个月内出现的无运动障碍。从患者的医疗记录中获得了关于静坐症发病的信息。分析CYP2D6基因型、阿立哌唑血药浓度、心得安、美托洛尔用药对静坐障碍发生的影响。纳入的患者在开始使用阿立哌唑之前已经服用了心得安和美托洛尔,并且不是用于治疗静坐症。结果:与未接受CYP2D6抑制剂治疗组(5.9%)和美托洛尔治疗组(7.1%)相比,接受心得安治疗的精神分裂症和分裂情感性障碍患者的无静坐症发生率(38.5%)显著高于接受心得安治疗组(5.9%)。在CYP2D6抑制剂中,只有服用心得安会增加静坐症的风险(Wald ch2 =5.5, p=0.02, OR=7.6 [95% CI=1.4-41.4])。多态性CYP2D6等位基因导致CYP2D6功能低下,与静坐症的发生呈统计学趋势水平相关(Wald Chi2=2.6, p=0.11, OR=4.7 [95% CI=0.7-30.8])。在随后的分析中,我们研究了心得安和CYP2D6基因型在静坐症发生中的可能相互作用。相互作用模型显示,心得安的作用不依赖于CYP2D6基因型(Wald Chi2=0.1, p=0.92),但其独立作用仍然显著(Wald Chi2=4.4, p=0.04)。结论:我们的研究结果表明,在阿立哌唑治疗期间,心得安用药增加了发生静坐障碍的风险。在阿立哌唑治疗期间避免使用心得安是至关重要的。然而,应该考虑两个主要的局限性:无静坐症没有使用标准化的临床评定量表进行评估,大多数患者(80.6%)接受了抗精神病药物联合治疗,这可能影响了研究结果。需要进一步的前瞻性研究来证实这些发现,这些发现是基于对阿立哌唑诱导的静坐症发展的回顾性、自然分析。
{"title":"Association of propranolol with treatment-emergent akathisia during aripiprazole treatment.","authors":"Ádám Menus, Ádám Kiss, Gábor Csukly, István Bitter, Katalin Monostory, János M Réthely","doi":"10.18071/isz.78.0395","DOIUrl":"https://doi.org/10.18071/isz.78.0395","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background and purpose: &lt;/strong&gt;Akathisia is a common side effect of aripiprazole treatment, which is associated with subjective distress for patients, and represents a frequent cause of treatment discontinuation. Propranolol and other beta-receptor blockers are commonly used for treatment of akathisia. Cytochrome P450 2D6 (CYP2D6) enzyme plays a major role in the metabolism of aripiprazole. Our previous study has shown that CYP2D6 inhibitory activity of beta-blockers (metoprolol and propranolol) may result in elevated aripiprazole plasma concentrations. The objective of the present retrospective study was to assess the prevalence of akathisia in patients receiving propranolol or metoprolol comedication, as well as in those not receiving any CYP2D6 inhibitors such as propranolol, metoprolol, risperidone.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Using the data of our previous pharmacogenetic study involving 67 patients diagnosed with schizophrenia or schizoaffective disorder and receiving aripiprazole treat- ment, we retrospectively investigated the emergence of akathisia within 6 months following aripiprazole initiation. Information on the onset of akathisia was obtained from patients' medical records. The effects of CYP2D6 genotype, aripiprazole plasma concentration, propranolol and metoprolol comedication on the development of akathisia were analysed. The included patients had already been taking propranolol and metoprolol comedication prior to the initiation of aripiprazole and not for the treatment of akathisia.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Schizophrenia and schizoaffective disorder patients treated with propranolol had a significantly higher incidence of documented akathisia (38,5%) compared to the group not receiving CYP2D6 inhibitors (5.9%), and the group treated with metoprolol comedication (7.1%). Among the CYP2D6 inhibitors, only the administration of propranolol increased the risk of akathisia (Wald Chi2=5.5, p=0.02, OR=7.6 [95% CI=1.4-41.4]). The polymorphic CYP2D6 alleles resulting in low CYP2D6 function showed a statistical trend-level association with the occurrence of akathisia (Wald Chi2=2.6, p=0.11, OR=4.7 [95% CI=0.7-30.8]). In a subsequent analysis, we investigated the possible interaction of propranolol and CYP2D6 genotypes on the development of akathisia. The interaction model showed that the effect of propranolol was not dependent on CYP2D6 genotype (Wald Chi2=0.1, p=0.92), however, its independent effect remained significant (Wald Chi2=4.4, p=0.04).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Our findings suggest that propranolol comedication increases the risk of the development of akathisia during aripiprazole treatment. It is of paramount importance to avoid propranolol comedication during aripiprazole treatment. However, two major limitations should be considered: akathisia was not assessed using a standardized clinical rating scale, and the majority of patients (80.6%) received antipsychotic combination therapy, which ma","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"78 11-12","pages":"395-404"},"PeriodicalIF":0.6,"publicationDate":"2025-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Can the prostate save the brain? When a disadvantage becomes an advantage]. 前列腺能拯救大脑吗?当劣势变成优势时]。
IF 0.6 4区 医学 Q4 CLINICAL NEUROLOGY Pub Date : 2025-11-30 DOI: 10.18071/isz.78.0389
Ildikó Palló, Attila Valikovics, Csaba Zsolt Oláh

Background and purpose: An unpleasant symptom of prostate hyperplasia is that older men get up to urinate at night. However, from the point of view of wake-up stroke, this can be an advantage, as they can detect their neurological deficit sooner due to the urge to urinate and can ask for help and receive definitive care sooner.

Methods: Between January 1. 2021 and May 30. 2024, at the Neurology Department of Borsod County University Teaching Hospital, we performed thrombolysis in 298 cases due to stroke within 4,5 hours.

Results: We treated 60.4% men and 39.6% women. In this period, we treated 61 wake-up stroke patients, 80.3% of them were men (all were more than 60 years old).

Conclusion: In our region more than four times as many male patients can receive definitive care as female patients with regard to wake-up stroke. The awakening caused by prostate hyperplasia can play an important role in detecting symptoms in time.

背景与目的:老年男性前列腺增生的一个令人不快的症状是夜间起床小便。然而,从醒脑卒中的角度来看,这可能是一个优势,因为他们可以更快地发现自己的神经功能缺陷,因为小便的冲动,可以请求帮助,并得到明确的护理更快。方法:1月1日~2021年和5月30日。2024年,在Borsod县大学教学医院神经内科,我们在4.5小时内对298例中风患者进行了溶栓治疗。结果:男性60.4%,女性39.6%。在此期间,我们治疗了61例醒脑患者,其中80.3%为男性(年龄均在60岁以上)。结论:在我们的地区,男性患者接受明确护理的人数是女性患者的四倍以上。前列腺增生引起的觉醒对及时发现症状有重要作用。
{"title":"[Can the prostate save the brain? When a disadvantage becomes an advantage].","authors":"Ildikó Palló, Attila Valikovics, Csaba Zsolt Oláh","doi":"10.18071/isz.78.0389","DOIUrl":"https://doi.org/10.18071/isz.78.0389","url":null,"abstract":"<p><strong>Background and purpose: </strong>An unpleasant symptom of prostate hyperplasia is that older men get up to urinate at night. However, from the point of view of wake-up stroke, this can be an advantage, as they can detect their neurological deficit sooner due to the urge to urinate and can ask for help and receive definitive care sooner.</p><p><strong>Methods: </strong>Between January 1. 2021 and May 30. 2024, at the Neurology Department of Borsod County University Teaching Hospital, we performed thrombolysis in 298 cases due to stroke within 4,5 hours.</p><p><strong>Results: </strong>We treated 60.4% men and 39.6% women. In this period, we treated 61 wake-up stroke patients, 80.3% of them were men (all were more than 60 years old).</p><p><strong>Conclusion: </strong>In our region more than four times as many male patients can receive definitive care as female patients with regard to wake-up stroke. The awakening caused by prostate hyperplasia can play an important role in detecting symptoms in time.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"78 11-12","pages":"389-393"},"PeriodicalIF":0.6,"publicationDate":"2025-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145649790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Ideggyogyaszati Szemle-Clinical Neuroscience
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1